BioSpyder Technologies

Executive Summary

BioSpyder Technologies has developed TempO-Seq™, a targeted sequencing platform for high-throughput gene expression profiling that can analyze hundreds to thousands of genes simultaneously from as few as single cells without pre-amplification. This technology enables pooling of up to 6,144 samples in a single run, offering significant cost and efficiency advantages for genomic research, particularly in oncology and drug development. Founded in 2010 and headquartered in Carlsbad, CA, the company targets the growing precision medicine market, where its ability to maximize precious sample utilization addresses a critical need. While BioSpyder has not disclosed funding or revenue data, its proprietary approach positions it well within the competitive genomics tools landscape, with potential applications in both research and clinical diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Commercial partnership with pharma or CRO for TempO-Seq adoption45% success
• Q4 2026Launch of single-cell TempO-Seq product enhancement30% success
• Q2 2026Series A or B funding round to scale commercialization25% success